X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Unichem Lab with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 UNICHEM LAB   MYLAN
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
MYLAN
Dec-14
UNICHEM LAB/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3343,861-   
Low Rs1742,721-   
Sales per share (Unadj.) Rs146.91,321.7-  
Earnings per share (Unadj.) Rs11.9159.2-  
Cash flow per share (Unadj.) Rs16.2256.3-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs105.1657.0-  
Shares outstanding (eoy) m90.84378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x1.72.5 69.4%   
Avg P/E ratio x21.420.7 103.3%  
P/CF ratio (eoy) x15.712.8 122.2%  
Price / Book Value ratio x2.45.0 48.2%  
Dividend payout %16.80-   
Avg Mkt Cap Rs m23,0731,245,149 1.9%   
No. of employees `0005.725.0 22.7%   
Total wages/salary Rs m2,5580-   
Avg. sales/employee Rs Th2,352.520,004.1 11.8%   
Avg. wages/employee Rs Th450.90-   
Avg. net profit/employee Rs Th190.42,409.8 7.9%   
INCOME DATA
Net Sales Rs m13,346500,102 2.7%  
Other income Rs m192-2,915 -6.6%   
Total revenues Rs m13,538497,187 2.7%   
Gross profit Rs m1,639124,378 1.3%  
Depreciation Rs m39036,730 1.1%   
Interest Rs m2921,572 0.1%   
Profit before tax Rs m1,41263,161 2.2%   
Minority Interest Rs m0-259 0.0%   
Prior Period Items Rs m-40-   
Extraordinary Inc (Exp) Rs m-350-   
Tax Rs m2932,656 11.0%   
Profit after tax Rs m1,08060,245 1.8%  
Gross profit margin %12.324.9 49.4%  
Effective tax rate %20.74.2 492.9%   
Net profit margin %8.112.0 67.2%  
BALANCE SHEET DATA
Current assets Rs m5,979439,655 1.4%   
Current liabilities Rs m2,432343,723 0.7%   
Net working cap to sales %26.619.2 138.6%  
Current ratio x2.51.3 192.2%  
Inventory Days Days6378 80.8%  
Debtors Days Days60107 56.3%  
Net fixed assets Rs m6,403115,697 5.5%   
Share capital Rs m18217,685 1.0%   
"Free" reserves Rs m9,2930-   
Net worth Rs m9,548248,600 3.8%   
Long term debt Rs m230371,384 0.1%   
Total assets Rs m12,8431,001,337 1.3%  
Interest coverage x50.03.9 1,273.7%   
Debt to equity ratio x01.5 1.6%  
Sales to assets ratio x1.00.5 208.1%   
Return on assets %8.68.2 105.7%  
Return on equity %11.324.2 46.7%  
Return on capital %14.313.6 105.2%  
Exports to sales %29.20-   
Imports to sales %6.30-   
Net fx Rs m3,1940-   
CASH FLOW
From Operations Rs m1,11965,739 1.7%  
From Investments Rs m-853-51,843 1.6%  
From Financial Activity Rs m-334-17,322 1.9%  
Net Cashflow Rs m-68-3,427 2.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare UNICHEM LAB With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare UNICHEM LAB With: LUPIN LTD  FULFORD INDIA  CADILA HEALTHCARE  J.B.CHEMICALS  PFIZER  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 21, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - CIPLA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS